[
  {
    "ts": null,
    "headline": "U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)",
    "summary": "Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), the first and only subcutaneously (SC) administered therapy for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).1 RYBREVANT FASPRO™ is approved across all indications of RYBREVANT® (amivantamab-vmjw).",
    "url": "https://finnhub.io/api/news?id=3563ff8fe26eb5f6240958cba87b161ef35f3f8a9bfacba772816ad029c6f990",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766015340,
      "headline": "U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)",
      "id": 137816802,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), the first and only subcutaneously (SC) administered therapy for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).1 RYBREVANT FASPRO™ is approved across all indications of RYBREVANT® (amivantamab-vmjw).",
      "url": "https://finnhub.io/api/news?id=3563ff8fe26eb5f6240958cba87b161ef35f3f8a9bfacba772816ad029c6f990"
    }
  },
  {
    "ts": null,
    "headline": "BofA Sees J&J’s Premium Multiple as Justified",
    "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 12 Best Dogs of the Dow to Invest in. On December 15, BofA raised its price target on Johnson & Johnson (NYSE:JNJ) to $220 from $204. The firm kept a Neutral rating. The firm says J&J’s premium multiple “looks appropriate for its growth plus asset mix.” It […]",
    "url": "https://finnhub.io/api/news?id=291e1378f772895e2405517ab5f477f589213957358924500e83e24c1d4f3ad3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765997403,
      "headline": "BofA Sees J&J’s Premium Multiple as Justified",
      "id": 137816803,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 12 Best Dogs of the Dow to Invest in. On December 15, BofA raised its price target on Johnson & Johnson (NYSE:JNJ) to $220 from $204. The firm kept a Neutral rating. The firm says J&J’s premium multiple “looks appropriate for its growth plus asset mix.” It […]",
      "url": "https://finnhub.io/api/news?id=291e1378f772895e2405517ab5f477f589213957358924500e83e24c1d4f3ad3"
    }
  },
  {
    "ts": null,
    "headline": "RIS Rx Appoints Stuart McGuigan to Board of Directors",
    "summary": "IRVINE, Calif., December 17, 2025--RIS Rx, a healthcare technology company offering gross-to-net (GTN) revenue protection and saving more than $1 billion for the world’s leading pharmaceutical manufacturers, today announced the appointment of Stuart McGuigan to its Board of Directors.",
    "url": "https://finnhub.io/api/news?id=c4ecceb16ca77128a679ed633422c6ee2f0fba21db1b0e9faad68ef01efc5ec5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765983600,
      "headline": "RIS Rx Appoints Stuart McGuigan to Board of Directors",
      "id": 137816804,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "IRVINE, Calif., December 17, 2025--RIS Rx, a healthcare technology company offering gross-to-net (GTN) revenue protection and saving more than $1 billion for the world’s leading pharmaceutical manufacturers, today announced the appointment of Stuart McGuigan to its Board of Directors.",
      "url": "https://finnhub.io/api/news?id=c4ecceb16ca77128a679ed633422c6ee2f0fba21db1b0e9faad68ef01efc5ec5"
    }
  },
  {
    "ts": null,
    "headline": "Share Offerings Prompt Huge Insider Buying in These 3 Biotechs",
    "summary": "Secondary offerings from biotechs Immunovant, Kymera Therapeutics, and Wave Life Sciences prompted some huge insider buying recently.",
    "url": "https://finnhub.io/api/news?id=adbf4ed72a5f619ea787682e7d1a7ff6a8c07998e2fffcbd941460c9691ba9ce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765982703,
      "headline": "Share Offerings Prompt Huge Insider Buying in These 3 Biotechs",
      "id": 137816805,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Secondary offerings from biotechs Immunovant, Kymera Therapeutics, and Wave Life Sciences prompted some huge insider buying recently.",
      "url": "https://finnhub.io/api/news?id=adbf4ed72a5f619ea787682e7d1a7ff6a8c07998e2fffcbd941460c9691ba9ce"
    }
  },
  {
    "ts": null,
    "headline": "Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?",
    "summary": "Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=dbb04bec287cf6dcf6f587ddf05df108c4c9064a6b887f25c44b85d97e846666",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765980006,
      "headline": "Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?",
      "id": 137816806,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=dbb04bec287cf6dcf6f587ddf05df108c4c9064a6b887f25c44b85d97e846666"
    }
  },
  {
    "ts": null,
    "headline": "LENZ Therapeutics: Was That A Market Overreaction?",
    "summary": "LENZ Therapeutics, Inc.'s VIZZ shows promise despite a recent adverse event. Click for LENZ investment insights, risks, and growth potential in the eye care market.",
    "url": "https://finnhub.io/api/news?id=d801ea9f6b245786b2045a893cf1791357a6ed5d3ff95f4fdb8128fa45cd8c6a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765962139,
      "headline": "LENZ Therapeutics: Was That A Market Overreaction?",
      "id": 137811317,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2197063554/image_2197063554.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "LENZ Therapeutics, Inc.'s VIZZ shows promise despite a recent adverse event. Click for LENZ investment insights, risks, and growth potential in the eye care market.",
      "url": "https://finnhub.io/api/news?id=d801ea9f6b245786b2045a893cf1791357a6ed5d3ff95f4fdb8128fa45cd8c6a"
    }
  },
  {
    "ts": null,
    "headline": "Heidi Hunter Appointed New Vice Chair of the Board of Directors of Bavarian Nordic",
    "summary": "COPENHAGEN, Denmark, December 17, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that, following the recent appointment of Anne Louise Eberhard as new Chair of the Board of Directors, and in accordance with the Company’s Articles of Association, the Board has convened and has appointed Ms. Heidi Hunter as new Vice Chair. Ms. Hunter has been a member of the board since 2023. She has over 25 years of industry experience, working across the pharmaceutical value chain, from clinical and comm",
    "url": "https://finnhub.io/api/news?id=f40f372d530a6273e58c086844f2ae9d33bcc6a1ca5b9a46519b452a5fe8c436",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765956600,
      "headline": "Heidi Hunter Appointed New Vice Chair of the Board of Directors of Bavarian Nordic",
      "id": 137816807,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "COPENHAGEN, Denmark, December 17, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that, following the recent appointment of Anne Louise Eberhard as new Chair of the Board of Directors, and in accordance with the Company’s Articles of Association, the Board has convened and has appointed Ms. Heidi Hunter as new Vice Chair. Ms. Hunter has been a member of the board since 2023. She has over 25 years of industry experience, working across the pharmaceutical value chain, from clinical and comm",
      "url": "https://finnhub.io/api/news?id=f40f372d530a6273e58c086844f2ae9d33bcc6a1ca5b9a46519b452a5fe8c436"
    }
  },
  {
    "ts": null,
    "headline": "GS Large Cap Value Fund Q3: Positioning For Sustained Momentum And Long-Term Growth",
    "summary": "GS Large Cap Value Fund underperformed in Q3 2025. Read on to know more about the top contributors, key detractors and new strategic positions.",
    "url": "https://finnhub.io/api/news?id=a67fc361956d556ed3210c3674797764fb5fe1594abf48deeb82aee8f41e7b19",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765940400,
      "headline": "GS Large Cap Value Fund Q3: Positioning For Sustained Momentum And Long-Term Growth",
      "id": 137809405,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2224140598/image_2224140598.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "GS Large Cap Value Fund underperformed in Q3 2025. Read on to know more about the top contributors, key detractors and new strategic positions. ",
      "url": "https://finnhub.io/api/news?id=a67fc361956d556ed3210c3674797764fb5fe1594abf48deeb82aee8f41e7b19"
    }
  }
]